Mucositis Clinical Trial
Official title:
A Phase I/II Study to Determine the Safety and Efficacy of Curcumin in Patients With Oral Mucositis Secondary to Chemotherapy
Oral mucositis is a common side effect from cancer treatment. Patients receiving chemotherapy
and radiotherapy can get very painful sores in their mouth that compromise nutrition and oral
hygiene as well as increase risk for infection, and can last for weeks. Currently, the only
treatment for mucositis is oral hygiene to try to support recovery.
Curcumin (also known as Turmeric) is a frequently-used spice in India and Southeast Asia.
Studies in cells and animals have shown that it can reduce the amount of bacteria and can
prevent inflammation.
In this study, the investigators want to learn if a mouthwash made with curcumin is safe for
people to use and if it can help their mucositis.
This is a phase I/II study involving 2 parts; a dose escalation to determine the maximum
tolerated dose (MTD) of curcumin and an expansion at the MTD.
Oral mucositis is a common and often debilitating complication associated with cancer
treatment. Treatment of mucositis is mainly supportive - oral hygiene is the means of
treatment. Curcumin (Turmeric), a frequently-used spice in India and Southeast Asia, can
reduce bacterial load and prevent inflammation in cultured epithelial cells and prevent
chemotherapy- and radiotherapy-induced mucositis in animal models.
The primary objective of this Phase I/II study is to determine the maximum tolerated dose
(MTD) of oral curcumin in patients who have chemotherapy-induced mucositis. The secondary
objectives of this study are to determine whether or not oral curcumin has an acceptable
safety profile or impacts oral mucositis health outcomes.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02252926 -
Local Anesthetic Treatment of Oral Pain in Patients With Mucositis
|
Phase 2 | |
| Completed |
NCT01155609 -
L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer
|
N/A | |
| Completed |
NCT00357942 -
Topical Morphine for Stomatitis-related Pain Induced by Chemotherapy
|
Phase 4 | |
| Completed |
NCT00360685 -
Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX
|
N/A | |
| Completed |
NCT04586491 -
The Effect of Oral Care Protocol on Prevention of Oral Mucositis in Pediatric Cancer Patients
|
N/A | |
| Withdrawn |
NCT02589860 -
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
|
||
| Not yet recruiting |
NCT02506231 -
The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome
|
Phase 2/Phase 3 | |
| Completed |
NCT02605382 -
Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis
|
Phase 2 | |
| Completed |
NCT02639377 -
Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis and Gingivitis
|
Phase 2 | |
| Terminated |
NCT02575313 -
The Effects of Whole Food Intervention on Mucositis in Patients Treated for Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00956254 -
Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis
|
Phase 3 | |
| Completed |
NCT00584597 -
A Trial of Homeopathic Medication TRAUMEEL S for the Treatment of Radiation-Induced Mucositis
|
Phase 1 | |
| Enrolling by invitation |
NCT05590117 -
Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer
|
Early Phase 1 | |
| Completed |
NCT05635929 -
Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients.
|
N/A | |
| Completed |
NCT05181943 -
Effectiveness of Photo-biomodulation in the Treatment of Chemotherapy Induced Mucositis
|
N/A | |
| Completed |
NCT03713567 -
Clinical, Immunological and Microbiological Evaluation of Experimental Gingivitis and Peri-implant Mucositis
|
N/A | |
| Completed |
NCT02671812 -
Outcome After Dental Implant Treatment
|
||
| Terminated |
NCT02273752 -
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
|
Phase 2 | |
| Recruiting |
NCT01707641 -
Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer
|
Phase 4 | |
| Completed |
NCT01015183 -
Prevention Chemotherapy Induced Mucositis by Zinc Sulfate
|
Phase 2/Phase 3 |